Prostate cancer is often resistant to immunotherapy, which harnesses a person’s immune system to recognize and destroy tumors. But a new technology that targets RNA in cancer cells gave immunotherapy new life, improving its ability to unleash cancer-killing cells in laboratory studies.

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the advanced stages of the disease still requires more precise tools. Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) have now tested a novel approach.

An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments—by lowering levels of a brain protein called tau, researchers reported Tuesday.

An analysis of the brain of a deceased Alzheimer’s disease (AD) clinical trial participant found that regions where an anti-amyloid therapy successfully cleared amyloid plaques showed little to no evidence of tau tangles, a hallmark of AD closely linked to neurodegeneration and cognitive decline.

More than 100,000 people in the United States are waiting for a lifesaving organ transplant. For patients who need a liver transplant, determining whether a donor liver is healthy enough to transplant is a critical part of the process.

Disease progression in people with Parkinson’s disease can be accurately monitored using sensors, removing some of the limitations of wearable technologies, a new study reports.